EGM
ZVRA icon

Engineers Gate Manager’s Zevra Therapeutics ZVRA Stock Holding History

Engineers Gate Manager’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,234
Closed -$366K – 2689
2026
Q1 		$366K Sell
39,234
-4,786
-11% -$43.1K ﹤0.01% 1600
2025
Q4 		$394K Buy
44,020
+8,359
+23% +$79.1K ﹤0.01% 1483
2025
Q3 		$339K Buy
+35,661
New +$358K ﹤0.01% 1695
2022
Q2 		– Sell
-22,700
Closed -$114K – 2309
2022
Q1 		$114K Buy
+22,700
New +$144K ﹤0.01% 1693
2021
Q4 		– Sell
-20,700
Closed -$193K – 2337
2021
Q3 		$193K Sell
20,700
-18,100
-47% -$182K 0.01% 1443
2021
Q2 		$497K Buy
38,800
+7,100
+22% +$76.3K 0.03% 831
2021
Q1 		$292K Buy
+31,700
New +$277K 0.01% 1337

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Engineers Gate Manager's ZVRA Position: Q2 2026 in Review

Engineers Gate Manager sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 39,234 shares — an estimated $366K sold.

Engineers Gate Manager first reported a position in ZVRA in Q1 2021 and held it in 7 quarters. The position peaked at $497K in Q2 2021. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Engineers Gate Manager reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 39,234 Zevra Therapeutics shares in Q2 2026, an estimated $366K.
  • Engineers Gate Manager first reported a position in Zevra Therapeutics in Q1 2021 and held it in 7 quarters.
  • Engineers Gate Manager's Zevra Therapeutics position peaked at $497K in Q2 2021.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.